We’re improving your experience!

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Drug Name CPX-351
Trade Name Vyxeos
Synonyms Liposome-encapsulated Daunorubicin-Cytarabine
Drug Descriptions

Vyxeos (CPX-351) is a liposomal formulation of cytarabine and daunorubicin with anti-tumor activities (PMID: 25223583). Vyxeos (CPX-351) is FDA approved for use in patients with newly-diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes (FDA.gov).

DrugClasses
CAS Registry Number NA
NCIT ID C67504

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Busulfan + CPX-351 + Fludarabine + Melphalan + Midostaurin Busulfan CPX-351 Fludarabine Melphalan Midostaurin 0 1
CPX-351 CPX-351 0 20
CPX-351 + Cytarabine + Filgrastim + Fludarabine CPX-351 Cytarabine Filgrastim Fludarabine 0 1
CPX-351 + Enasidenib CPX-351 Enasidenib 0 2
CPX-351 + Gemtuzumab ozogamicin CPX-351 Gemtuzumab ozogamicin 0 6
CPX-351 + Gilteritinib CPX-351 Gilteritinib 0 1
CPX-351 + Glasdegib CPX-351 Glasdegib 0 1
CPX-351 + Ivosidenib CPX-351 Ivosidenib 0 1
CPX-351 + Midostaurin CPX-351 Midostaurin 0 1
CPX-351 + Palbociclib CPX-351 Palbociclib 0 1
CPX-351 + Palbociclib + Tazemetostat CPX-351 Palbociclib Tazemetostat 0 1
CPX-351 + Quizartinib CPX-351 Quizartinib 0 2
CPX-351 + Ruxolitinib CPX-351 Ruxolitinib 0 1
CPX-351 + Venetoclax CPX-351 Venetoclax 0 5


Additional content available in Icon for CKB-BoostCKB BOOST